Pharmaceuticals

Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023

* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...

2023-08-30 00:04 1676

Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023

* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...

2023-08-30 00:02 1222

Viva Biotech (1873.HK) Announces 2023 Interim Results:Solid Growth in Main Business, Significant Rebound in Profitability

Highlights of the Interim Results as of June 30, 2023: * Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% * Gross profit amounted to RMB406.0 million, representing a year-on-year increase of approximately 17.7% * Adjusted Non-IFRS net profit amo...

2023-08-29 22:38 2555

Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC

HONG KONG, Aug. 29, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced completion of patient enrollment in a head-to-head study of ivonescimab (AK112, PD-1/VEGF bispecific antibody) compared with pembrolizumab as first-line treatment for patients with PD-L1 positive (PD-L1 TPS≥1%) loca...

2023-08-29 20:00 1352

Bayer Launches Stunting Prevention Program "CETING" for Community of Cisalak, Depok

DEPOK, Indonesia, Aug. 29, 2023 /PRNewswire/ -- Bayer, a global Life Science company in health and nutrition, is taking an active role in addressing the stunting problem inIndonesia. Coinciding with Bayer's 66th year in Indonesia, Bayer launched the CETING (Prevent Stunting) program for the commu...

2023-08-29 13:53 2041

ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference

SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings at the Morgan Stanley 21st Annual Global Healthca...

2023-08-28 20:00 1260

Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines

The 2023 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) include upgraded recommendations for intravenous (IV) iron supplementation, including Ferinject® (ferric carboxymaltose), for the management of iron deficiency in patients with HF. Phase IV HEART-FI...

2023-08-28 19:00 2250

Harbour BioMed Announces 2023 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...

2023-08-28 17:08 2447

Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed (the"Company", HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to commence clinical trials of its first antib...

2023-08-28 16:30 1488

Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress

TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023. During the reporting period, the company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", rapidly promoted pr...

2023-08-28 11:08 3000

Specialised Therapeutics acquires commercialisation rights to new oral MND therapy

.. ST to partner with Dutch biotech company Treeway BV .. First CNS therapy in ST therapeutic portfolio SINGAPORE, Aug. 27, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withNetherlands based biotechnology company Treeway BV to...

2023-08-28 04:00 1632

First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial

Highlights * First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq. * Cohort 2 was recently completed in 3 participants who received therapy...

2023-08-25 20:58 2711

Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA

HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that the National Center for Drug Evaluatio...

2023-08-25 20:00 2240

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its interim results for the six-months endedJune 30, 2023, and provided updates on multiple milestones achieved since the beginning of 2023. Dr. Jay Mei, Antengene's F...

2023-08-25 19:37 2354

Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth

SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 interim results. In the first half of 2023, Henlius reported a boost in operating profits ofRMB240.0 million and revenues of RMB2.5005 billion, up by 93.9% YoY, driven by growth in core oncology products. HANQUYOU (trast...

2023-08-25 19:26 5612

Tigermed Reports 2023 Interim Results

HANGZHOU, China, Aug. 25, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its int...

2023-08-25 18:39 3604

GC Biopharma to Produce Cholera Vaccines Jointly with Eubiologics

YONGIN, South Korea, Aug. 25, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a MOU at its headquarters in Yongin,South Korea with Eubiologics for a co-production of Euvichol, an oral cholera vaccine. Under the MOU, bo...

2023-08-25 15:14 1624

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced

HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximatelyRMB3,783.8 million, up 22.3% on a yearly basis. Gross profit was approximatelyRMB3,201.6 million, up ...

2023-08-25 10:06 4478

Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon® for the Treatment of Primary IgA Nephropathy

SHANGHAI, Aug. 25, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that the Ph...

2023-08-25 08:15 2269

Antheia Achieves Major Commercial Milestone

Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMs and APIs MENLO PARK, Calif., Aug. 25, 2023 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the...

2023-08-25 08:01 2038
1 ... 82838485868788 ... 314